4-(4-chlorophenoxy)benzoyl chloride | 68548-52-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-chlorophenoxy)benzoyl chloride
• CAS: 68548-52-7
• 化学式: C₁₃H₈Cl₂O₂
• 分子量: 267.111
• InChiKey: MXACHZKCBUUPMG-UHFFFAOYSA-N

物化性质

• 沸点：
  185 °C(Press: 0.5 Torr)
• 密度：
  1.346±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-chlorophenoxy)benzoyl chloride 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 mineral oil 为溶剂， 反应 24.5h， 生成 benzyl 3-(5-amino-3-(4-(4-chlorophenoxy)phenyl)-4-cyano-1H-pyrazol-1-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] BRUTON'S TYROSINE KINASE INHIBITORS
  [FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON

  摘要：

  本文披露了一种与Bruton's酪氨酸激酶（BTK）形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症，包括淋巴瘤，以及炎症性疾病或症状的方法。 (化学式I)

  公开号：

  WO2014068527A1
• 作为产物：
  描述：

  4-(4-氯苯氧基)苄腈 在 氯化亚砜 、 双氧水 、 potassium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 28.0h， 生成 4-(4-chlorophenoxy)benzoyl chloride
  参考文献：
  名称：

  黄酮作为4（1 H）-喹诺酮类的等排体：发现有效的配体和双阶段抗疟铅化合物

  摘要：

  疟疾每年导致近一百万人死亡，恶性疟原虫的多抗性菌株的日益流行给控制该疾病带来了巨大挑战。制备了与4（1 H）-喹诺酮等排的多种黄酮，并对其抗恶性疟原虫W2菌株的血液阶段和鼠寄生虫伯氏疟原虫的肝脏阶段的抗疟原虫活性进行了分析。配体有效的潜在客户被确定为双阶段抗疟药，这表明支架优化可以提供有效的抗疟原虫化合物。

  DOI：

  10.1016/j.ejmech.2013.09.008

文献信息

• [EN] BRUTON'S TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PFIZER

  公开号：WO2014068527A1

  公开（公告）日：2014-05-08

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

  本文披露了一种与Bruton's酪氨酸激酶（BTK）形成共价键的化合物。公开了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。公开了使用BTK抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症，包括淋巴瘤，以及炎症性疾病或症状的方法。 (化学式I)
• Bruton's Tyrosine Kinase Inhibitors
  申请人：PFIZER INC.

  公开号：US20150291554A1

  公开（公告）日：2015-10-15

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。披露了制备这些化合物的方法。还披露了包括这些化合物的药物组合物。披露了使用BTK抑制剂的方法，单独或与其他治疗剂一起，用于治疗自身免疫性疾病或状况、异种免疫性疾病或状况、包括淋巴瘤的癌症和炎症性疾病或状况。
• Bruton's tyrosine kinase inhibitors
  申请人：Pfizer Inc.

  公开号：US10266513B2

  公开（公告）日：2019-04-23

  Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文公开了与布鲁顿酪氨酸激酶（BTK）形成共价键的化合物。还公开了制备这些化合物的方法。还公开了包括这些化合物的药物组合物。本发明公开了使用BTK抑制剂的方法，这些抑制剂可单独使用，也可与其它治疗剂联合使用，用于治疗自身免疫性疾病或病症、异种免疫性疾病或病症、癌症（包括淋巴瘤）以及炎症性疾病或病症。
• Addressing cytotoxicity of 1,4-biphenyl amide derivatives: Discovery of new potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors
  作者：Emanuele Marco Gargano、Enrico Perspicace、Angelo Carotti、Sandrine Marchais-Oberwinkler、Rolf W. Hartmann

  DOI：10.1016/j.bmcl.2015.11.047

  日期：2016.1

  Four different classes of new 17 beta-hydroxysteroid dehydrogenase type 2 (17 beta-HSD2) inhibitors were synthesized, in order to lower the cytotoxicity exhibited by the lead compound A, via disrupting the linearity and the aromaticity of the biphenyl moiety. Compounds 3, 4, 7a and 8 displayed comparable or better inhibitory activity and selectivity, as well as a lower cytotoxic effect, compared to the reference compound A. The best compound 4 (IC50 = 160 nM, selectivity factor = 168, LD50 approximate to 25 mu M) turned out as new lead compound for inhibition of 17 beta-HSD2. (C) 2015 Elsevier Ltd. All rights reserved.
• Synthesis and biological activity of a series of diaryl-substituted .alpha.-cyano-.beta.-hydroxypropenamides, a new class of anthelmintic agents
  作者：Eric B. Sjogren、Michael A. Rider、Peter H. Nelson、Stanford Bingham、Anthony L. Poulton、Mark A. Emanuel、Richard Komuniecki

  DOI：10.1021/jm00115a020

  日期：1991.11

  A series of alpha-cyano-beta-hydroxypropenamides was prepared and tested for anthelmintic activity. Alpha-cyano-beta-hydroxy hydroxy-N-[4-(trifluoromethyl)phenyl]-3-[4-(trifluoromethyl)phenyl]propenamide (1) showed good activity against the nematode Nematospirodes dubius in a mixed parasite infection in mice; several of the analogues were also effective against the cestode Hymenolepis nana. In sheep trials, 1 caused 100% reduction of the hematophagous nematode Haemonchus contortus after a single dose of 20 mg/kg but did not show satisfactory control of Trichostrongylus colubriformis or Ostertagia circumcincta. Against the liver fluke Fasciola hepatica, 1 suppressed egg production but only temporarily, suggesting that the adult flukes were not eliminated. Mechanism of action studies on 1 using Ascaris mitochondria showed it to be an uncoupler of oxidative phosphorylation.